{"id":"north-star","safety":{"commonSideEffects":[{"rate":"0.1-0.5%","effect":"Increased risk of diabetic ketoacidosis"},{"rate":"1-5%","effect":"Increased risk of genital yeast infections"},{"rate":"2-10%","effect":"Increased risk of urinary tract infections"},{"rate":"5-20%","effect":"Nausea"},{"rate":"2-10%","effect":"Vomiting"},{"rate":"5-20%","effect":"Diarrhea"},{"rate":"5-20%","effect":"Abdominal pain"},{"rate":"5-20%","effect":"Fatigue"},{"rate":"5-20%","effect":"Headache"},{"rate":"2-10%","effect":"Muscle cramps"}]},"_chembl":null,"_dailymed":{"setId":"a216c557-3607-c716-e053-2a95a90a3788","title":"OLD SPICE NORTH STAR (ALUMINUM ZIRCONIUM TRICHLOROHYDREX GLY) STICK [THE PROCTER & GAMBLE MANUFACTURING COMPANY]"},"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting SGLT2, North Star reduces glucose reabsorption in the kidneys, leading to increased glucose excretion in the urine and decreased glucose levels in the blood. This mechanism is particularly beneficial for patients with type 2 diabetes, as it helps to lower blood sugar levels and improve glycemic control.","oneSentence":"North Star is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2).","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:40:01.793Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of type 2 diabetes"},{"name":"Reduction of major adverse cardiovascular events in adults with established cardiovascular disease or multiple cardiovascular risk factors"}]},"trialDetails":[{"nctId":"NCT05874466","phase":"","title":"SenseToKnow Autism Screening Device Validation Study","status":"RECRUITING","sponsor":"Duke University","startDate":"2023-07-07","conditions":"Autism, Autism Spectrum Disorder","enrollment":350},{"nctId":"NCT03992430","phase":"PHASE3","title":"A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participants With Duchenne Muscular Dystrophy (DMD) (MIS51ON)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2020-07-13","conditions":"Muscular Dystrophy, Duchenne","enrollment":160},{"nctId":"NCT05712421","phase":"PHASE2","title":"A Study Evaluation the Safety and Efficacy of Hormone Replacement Therapy With North Star Compared to Levothyroxine in Patients With Primary Hypothyroidism","status":"COMPLETED","sponsor":"Neuvosyn Laboratories, LLC","startDate":"2023-02-28","conditions":"Hypothyroidism","enrollment":303},{"nctId":"NCT04475926","phase":"","title":"A Study of the Natural History of Participants With LGMD2E/R4, LGMD2D/R3, LGMD2C/R5, and LGMD2A/R1 ≥ 4 Years of Age, Who Are Managed in Routine Clinical Practice","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2021-04-22","conditions":"Limb-girdle Muscular Dystrophy","enrollment":205},{"nctId":"NCT07188012","phase":"EARLY_PHASE1","title":"Safety and Dystrophin Expression of SPOT-mRNA03 in Duchenne Muscular Dystrophy (DMD) Patients","status":"RECRUITING","sponsor":"Shanghai Siponuoyin Biotechnology Co Ltd","startDate":"2025-08-06","conditions":"Duchenne Muscular Dystrophy (DMD)","enrollment":6},{"nctId":"NCT05593484","phase":"NA","title":"School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Alaska","status":"RECRUITING","sponsor":"University of Arkansas","startDate":"2023-09-01","conditions":"Hearing Loss","enrollment":8060},{"nctId":"NCT05096221","phase":"PHASE3","title":"A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)","status":"COMPLETED","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2021-10-27","conditions":"Duchenne Muscular Dystrophy","enrollment":126},{"nctId":"NCT05881408","phase":"PHASE3","title":"A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) in Non-Ambulatory and Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2023-05-31","conditions":"Duchenne Muscular Dystrophy","enrollment":148},{"nctId":"NCT06054971","phase":"","title":"NSAA NON-Interventional Study Protocol","status":"COMPLETED","sponsor":"Red Nucleus Enterprise Solutions, LLC","startDate":"2023-10-02","conditions":"Duchenne Muscular Dystrophy","enrollment":31},{"nctId":"NCT03769116","phase":"PHASE1, PHASE2","title":"A Randomized, Double-blind, Placebo-controlled Study of Delandistrogene Moxeparvovec (SRP-9001) for Duchenne Muscular Dystrophy (DMD)","status":"COMPLETED","sponsor":"Sarepta Therapeutics, Inc.","startDate":"2018-12-05","conditions":"Muscular Dystrophy, Duchenne","enrollment":41},{"nctId":"NCT02780492","phase":"","title":"Outcome Measures in Duchenne Muscular Dystrophy: A Natural History Study","status":"COMPLETED","sponsor":"University College, London","startDate":"2012-04-11","conditions":"Duchenne Muscular Dystrophy","enrollment":35},{"nctId":"NCT05798325","phase":"NA","title":"Feasibility, Validation and Application of Digital Tools for the Follow-up of Neuromuscular Patient Mobility in Daily Living","status":"UNKNOWN","sponsor":"Institut de Myologie, France","startDate":"2023-06-29","conditions":"Neuromuscular Diseases","enrollment":40},{"nctId":"NCT05549999","phase":"","title":"Cultural Adaptation, Validity, and Reliability of the Turkish Version of North Star Ambulatory Assessment","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2022-11-01","conditions":"Duchenne Muscular Dystrophy, Ambulation Difficulty, Ambulation Disorder, Neurologic","enrollment":86},{"nctId":"NCT05436210","phase":"","title":"Postural and Anthropometric Properties of Foot and Ankle of Patients With DMD","status":"COMPLETED","sponsor":"Hacettepe University","startDate":"2022-06-23","conditions":"Duchenne Muscular Dystrophy, Ambulation Difficulty, Posture Disorders in Children","enrollment":48},{"nctId":"NCT03662165","phase":"NA","title":"Increase HIV Testing Among Truck Drivers and Female Sex Workers in Kenya Through Offering HIV Self-Testing","status":"COMPLETED","sponsor":"City University of New York, School of Public Health","startDate":"2016-12-20","conditions":"HIV Testing","enrollment":4458}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":259,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"North Star","genericName":"North Star","companyName":"Neuvosyn Laboratories, LLC","companyId":"neuvosyn-laboratories-llc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"North Star is a small molecule that acts as a selective inhibitor of the sodium-glucose cotransporter 2 (SGLT2). Used for Treatment of type 2 diabetes, Reduction of major adverse cardiovascular events in adults with established cardiovascular disease or multiple cardiovascular risk factors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}